Semaglutide has been approved for reducing kidney disease progression and cardiovascular risk in patients with type 2 diabetes, marking a significant advancement in CKD management.

Identifying and managing IVIG-related side effects early on in treatment can improve efficacy and safety for patients with CIDP.

Phil Vigeant shares insights on the health benefits of protein supplements and guidance for consumers to identify safe and effective protein powder products.

Donna Ryan explains why long-term treatment with GLP-1 medication is typically necessary to maintain weight loss benefits.

Future research can explore the underlying cause of recurrent pericarditis with systemic Sjögren syndrome and the combination of rilonacept with immunosuppressive therapies.

Steven Pipe, MD, explains the long-term efficacy data surrounding etranacogene dezaparvovec in patients with hemophilia B.

Pharmacists can help educate patients, identify adverse events, and help patients communicate with other health care professionals or drug companies.

Richard Lewis discusses the critical role pharmacists and health care providers play in ensuring safe administration of IVIG for patients with CIDP.